Ourania Tatsis - 10 Feb 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
10 Feb 2023
Net transactions value
-$1,380,804
Form type
4
Filing time
14 Feb 2023, 16:12:20 UTC
Previous filing
03 Feb 2023
Next filing
16 Feb 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability $405,292 -1,377 -2% $294.33 69,035 10 Feb 2023 Direct
transaction VRTX Common Stock Tax liability $893,289 -2,995 -4.3% $298.26 66,040 13 Feb 2023 Direct
transaction VRTX Common Stock Sale $592 -2 -0% $295.84 66,038 13 Feb 2023 Direct F1
transaction VRTX Common Stock Sale $23,253 -78 -0.12% $298.11 65,960 13 Feb 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale $35,878 -120 -0.18% $298.98 65,840 13 Feb 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale $19,192 -64 -0.1% $299.88 65,776 13 Feb 2023 Direct F1, F2, F5
transaction VRTX Common Stock Sale $3,309 -11 -0.02% $300.79 65,765 13 Feb 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1.
F2 Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $298.11 (range $297.51 to $298.50).
F4 Open market sales reported on this line occurred at a weighted average price of $298.98 (range $298.53 to $299.50).
F5 Open market sales reported on this line occurred at a weighted average price of $299.88 (range $299.62 to $300.53).